U.S. Primary Care Clinics’ Experiences During Introduction of the 9-Valent HPV Vaccine

Melanie L. Kornides, William A. Calo, Jennifer A. Heisler-MacKinnon, Melissa B. Gilkey

Research output: Contribution to journalArticle

Abstract

Changes in the routine immunization schedule are common and may pose challenges to primary care clinics. We sought to assess the experiences of U.S. providers and clinic staff during the introduction of 9-valent HPV vaccine. In 2015–2016, we conducted a survey in a probability sample of 127 pediatric (40%) and family medicine (60%) clinics in three U.S. states. The 211 respondents included clinicians (63%) and staff (37%). Overall, 83% of clinics stocked 9-valent HPV vaccine, with adoption ranging from 60% among early respondents to 100% among later respondents. Almost all respondents believed that providers in their clinics would recommend the 9-valent vaccine as strongly as (66%) or more strongly than (33%) the quadrivalent vaccine. Over half (61%) had no concerns about the 9-valent vaccine, while others reported concerns about increased parental hesitancy (29%), private insurance coverage (17%), or other issues (10%). Respondents from pediatric versus family medicine clinics more often reported a concern (OR = 2.06, 95% CI 1.02–4.15). Among the 169 respondents who stocked 9-valent vaccine, about half (56%, n = 94) anticipated that providers in their clinics would recommend a “booster” dose of 9-valent HPV vaccine for adolescents who had completed the 3-dose series with prior versions. Among the 42 respondents who did not stock 9-valent vaccine, few (17%, n = 7) believed providers would recommend adolescents delay vaccination until it was available. In conclusion, providers and staff generally had positive views of 9-valent HPV vaccine and many had no concerns. For others, responses regarding parental hesitancy, insurance coverage, and the use of booster doses suggests opportunities for enhancing future educational support.

Original languageEnglish (US)
Pages (from-to)291-296
Number of pages6
JournalJournal of Community Health
Volume43
Issue number2
DOIs
StatePublished - Apr 1 2018

Fingerprint

Papillomavirus Vaccines
Primary Health Care
insurance coverage
staff
Vaccines
medicine
adolescent
experience
vaccination
Insurance Coverage
Medicine
Pediatrics
Immunization Schedule
Sampling Studies
Surveys and Questionnaires
Vaccination

All Science Journal Classification (ASJC) codes

  • Health(social science)
  • Public Health, Environmental and Occupational Health

Cite this

Kornides, Melanie L. ; Calo, William A. ; Heisler-MacKinnon, Jennifer A. ; Gilkey, Melissa B. / U.S. Primary Care Clinics’ Experiences During Introduction of the 9-Valent HPV Vaccine. In: Journal of Community Health. 2018 ; Vol. 43, No. 2. pp. 291-296.
@article{05569e32399f4e2287009e6536fbddbe,
title = "U.S. Primary Care Clinics’ Experiences During Introduction of the 9-Valent HPV Vaccine",
abstract = "Changes in the routine immunization schedule are common and may pose challenges to primary care clinics. We sought to assess the experiences of U.S. providers and clinic staff during the introduction of 9-valent HPV vaccine. In 2015–2016, we conducted a survey in a probability sample of 127 pediatric (40{\%}) and family medicine (60{\%}) clinics in three U.S. states. The 211 respondents included clinicians (63{\%}) and staff (37{\%}). Overall, 83{\%} of clinics stocked 9-valent HPV vaccine, with adoption ranging from 60{\%} among early respondents to 100{\%} among later respondents. Almost all respondents believed that providers in their clinics would recommend the 9-valent vaccine as strongly as (66{\%}) or more strongly than (33{\%}) the quadrivalent vaccine. Over half (61{\%}) had no concerns about the 9-valent vaccine, while others reported concerns about increased parental hesitancy (29{\%}), private insurance coverage (17{\%}), or other issues (10{\%}). Respondents from pediatric versus family medicine clinics more often reported a concern (OR = 2.06, 95{\%} CI 1.02–4.15). Among the 169 respondents who stocked 9-valent vaccine, about half (56{\%}, n = 94) anticipated that providers in their clinics would recommend a “booster” dose of 9-valent HPV vaccine for adolescents who had completed the 3-dose series with prior versions. Among the 42 respondents who did not stock 9-valent vaccine, few (17{\%}, n = 7) believed providers would recommend adolescents delay vaccination until it was available. In conclusion, providers and staff generally had positive views of 9-valent HPV vaccine and many had no concerns. For others, responses regarding parental hesitancy, insurance coverage, and the use of booster doses suggests opportunities for enhancing future educational support.",
author = "Kornides, {Melanie L.} and Calo, {William A.} and Heisler-MacKinnon, {Jennifer A.} and Gilkey, {Melissa B.}",
year = "2018",
month = "4",
day = "1",
doi = "10.1007/s10900-017-0420-x",
language = "English (US)",
volume = "43",
pages = "291--296",
journal = "Journal of Community Health",
issn = "0094-5145",
publisher = "Springer Netherlands",
number = "2",

}

U.S. Primary Care Clinics’ Experiences During Introduction of the 9-Valent HPV Vaccine. / Kornides, Melanie L.; Calo, William A.; Heisler-MacKinnon, Jennifer A.; Gilkey, Melissa B.

In: Journal of Community Health, Vol. 43, No. 2, 01.04.2018, p. 291-296.

Research output: Contribution to journalArticle

TY - JOUR

T1 - U.S. Primary Care Clinics’ Experiences During Introduction of the 9-Valent HPV Vaccine

AU - Kornides, Melanie L.

AU - Calo, William A.

AU - Heisler-MacKinnon, Jennifer A.

AU - Gilkey, Melissa B.

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Changes in the routine immunization schedule are common and may pose challenges to primary care clinics. We sought to assess the experiences of U.S. providers and clinic staff during the introduction of 9-valent HPV vaccine. In 2015–2016, we conducted a survey in a probability sample of 127 pediatric (40%) and family medicine (60%) clinics in three U.S. states. The 211 respondents included clinicians (63%) and staff (37%). Overall, 83% of clinics stocked 9-valent HPV vaccine, with adoption ranging from 60% among early respondents to 100% among later respondents. Almost all respondents believed that providers in their clinics would recommend the 9-valent vaccine as strongly as (66%) or more strongly than (33%) the quadrivalent vaccine. Over half (61%) had no concerns about the 9-valent vaccine, while others reported concerns about increased parental hesitancy (29%), private insurance coverage (17%), or other issues (10%). Respondents from pediatric versus family medicine clinics more often reported a concern (OR = 2.06, 95% CI 1.02–4.15). Among the 169 respondents who stocked 9-valent vaccine, about half (56%, n = 94) anticipated that providers in their clinics would recommend a “booster” dose of 9-valent HPV vaccine for adolescents who had completed the 3-dose series with prior versions. Among the 42 respondents who did not stock 9-valent vaccine, few (17%, n = 7) believed providers would recommend adolescents delay vaccination until it was available. In conclusion, providers and staff generally had positive views of 9-valent HPV vaccine and many had no concerns. For others, responses regarding parental hesitancy, insurance coverage, and the use of booster doses suggests opportunities for enhancing future educational support.

AB - Changes in the routine immunization schedule are common and may pose challenges to primary care clinics. We sought to assess the experiences of U.S. providers and clinic staff during the introduction of 9-valent HPV vaccine. In 2015–2016, we conducted a survey in a probability sample of 127 pediatric (40%) and family medicine (60%) clinics in three U.S. states. The 211 respondents included clinicians (63%) and staff (37%). Overall, 83% of clinics stocked 9-valent HPV vaccine, with adoption ranging from 60% among early respondents to 100% among later respondents. Almost all respondents believed that providers in their clinics would recommend the 9-valent vaccine as strongly as (66%) or more strongly than (33%) the quadrivalent vaccine. Over half (61%) had no concerns about the 9-valent vaccine, while others reported concerns about increased parental hesitancy (29%), private insurance coverage (17%), or other issues (10%). Respondents from pediatric versus family medicine clinics more often reported a concern (OR = 2.06, 95% CI 1.02–4.15). Among the 169 respondents who stocked 9-valent vaccine, about half (56%, n = 94) anticipated that providers in their clinics would recommend a “booster” dose of 9-valent HPV vaccine for adolescents who had completed the 3-dose series with prior versions. Among the 42 respondents who did not stock 9-valent vaccine, few (17%, n = 7) believed providers would recommend adolescents delay vaccination until it was available. In conclusion, providers and staff generally had positive views of 9-valent HPV vaccine and many had no concerns. For others, responses regarding parental hesitancy, insurance coverage, and the use of booster doses suggests opportunities for enhancing future educational support.

UR - http://www.scopus.com/inward/record.url?scp=85028599221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028599221&partnerID=8YFLogxK

U2 - 10.1007/s10900-017-0420-x

DO - 10.1007/s10900-017-0420-x

M3 - Article

C2 - 28856551

AN - SCOPUS:85028599221

VL - 43

SP - 291

EP - 296

JO - Journal of Community Health

JF - Journal of Community Health

SN - 0094-5145

IS - 2

ER -